Navigation Links
M2S Announces Agreement with AG Mednet to Provide Clinical Trial Sponsors with More Options for Efficient Image Transfer and Collection
Date:4/7/2009

man, President & CEO of AG Mednet added that his company is pleased to be working with M2S.

"The AG Mednet web-enabled network, together with its powerful workflow and de-identification capabilities, is rapidly becoming the standard software-based image delivery platform, and will provide M2S with a highly scalable solution to fit the needs of the most demanding global trials," said Gutman.

Clinical trials are increasingly using medical imaging for inclusion criteria, secondary and surrogate endpoints and to serve as adjunctive safety assessment of drugs under development. Imaging provides a non-invasive method of obtaining information on a drug's effects in the body and can provide crucial information for making early "go/no-go" decisions, potentially saving millions of dollars in development costs. Collecting and managing large amounts of imaging data securely and rapidly can be challenging and often costly for trial sponsors, and the traditional method of image transfer via hard media and courier services is very time-intensive and error prone. Electronic data transfer of images drastically reduces the time involved, provides the opportunity for early discovery and resolution of queries, and therefore can provide significant cost savings in clinical trials.

M2S has been utilizing web-based methods for rapid and secure electronic image collection and transfer since 2002, with their proprietary network transfer device, the DICOM Armor Car (DAC®), which has an installed base of 287 sites worldwide. The AG Mednet network, in use at over 600 investigator sites globally, provides a web-enabled site interface allowing investigators to de-identify exams, fill electronic transmittal forms and submit the data directly to M2S trial repositories. Whether a trial is a Phase I using imaging for inclusion criteria, or a Phase III multi-center international study with multiple imaging modalities for surrogate endpoints, M
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Immucor Announces Fiscal Third Quarter Results
2. IGI Announces Portal Designed to Maximize Data Sharing Between Hospitals and Their Affiliated Physicians
3. iMedica Announces New Leadership for Regional Sales Teams
4. TeleTracking Announces Next Generation Bed Management Solution at HIMSS 09
5. Haemonetics Announces Change to Board of Directors
6. Cord Blood Announces $1.75 Million Reduction in Long Term Debt
7. FFF Named the Exclusive Distributor of Fluzone for GPOs & Announces New Fluzone Return Policy
8. Siemens Announces Latest Contracts, Recent Go Lives, and Strong Customer Support for its Workflow-Enhancing Healthcare IT Solution Soarian Clinicals, at HIMSS 2009
9. Schiff Announces New Trip of a Lifetime Sweepstakes
10. Male Hormone Treatment Provider Announces Family Doctor Alert
11. Microsoft Windows Embedded Announces Winner of SPARKs Will Fly Developer Contest
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
M2S Announces Agreement with AG Mednet to Provide Clinical Trial Sponsors with More Options for Efficient Image Transfer and Collection
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... Consumer demand for healthy lifestyle drives new store openings, ... new year means,a new resolution or two. For GNC, ... the supplement industry is expected to rise steadily,through 2012, ... time for GNC to once again expand its store ...
... Phase 2 Clinical Trials,Dow AgroSciences CEO Discusses Future Opportunities ... Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) announced that the ... and preview objectives for 2008 during its,annual Investor and ... Jerome Peribere, President and CEO of Dow AgroSciences will ...
... a division of Wyeth (NYSE: WYE ), ... leading scientific and pharmaceutical,achievements at the third annual ... 4. Wyeth received honors for Best Overall Pipeline, ... by Scrip World Pharmaceutical News,a leading source of ...
... -- Apart from a more complicated medical case, ... time with their patients" Researchers at UC Davis ... that affect the length of a patients medical ... the doctors visit. , In a new ...
... Drug has significant risks, and its benefits are still debated, ... U.S. Food and Drug Administration advisory panel recommended Wednesday that ... women with advanced breast cancer. , In a close vote, ... the growth of tumors did not outweigh the increased risk ...
... two Phase III clinical trials support that Asacol, an ... agents known as 5-aminosalicylic acids (5-ASAs), is an effective ... ulcerative colitis (UC), including isolated proctitis. The results ... dosed at 2.4 g/day for six weeks, experienced significant ...
Cached Medicine News:Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 3Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 4Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 5Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 6Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 7Health News:Wyeth Receives Honors at the 2007 Scrip Awards 2Health News:Wyeth Receives Honors at the 2007 Scrip Awards 3Health News:Wyeth Receives Honors at the 2007 Scrip Awards 4Health News:Wyeth Receives Honors at the 2007 Scrip Awards 5Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:Asacol treats UC symptoms of isolated proctitis 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 21 More than one in three diabetes ... prescribed, stating that they have done so on average three ... estimate that in reality this number could be as high ... and Physicians in Insulin Therapy (GAPP™) survey, released today by ...
... WESTLAKE VILLAGE, Calif., Sept. 21 As consumer ... on overall pharmacy customer satisfaction has increased considerably ... Associates 2010 U.S. National Pharmacy Study(SM) released today. ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) The ...
Cached Medicine Technology:New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 2New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 2J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 4J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 5
... (PNET) is the foundation and supporting ... systems. This extremely versatile software supports ... for all the GI diagnostic testing ... and catheter-based ambulatory pH testing, esophageal ...
Symbia T, a TruePoint SPECTCT system, combines a dual-detector variable angle gamma camera with a CT scanner optimized for rapid, accurate attenuation correction of the nuclear data....
... STAT analyzer and data management system ... meet the traditional needs of data management ... for the management of STAT analyzer systems., ... simple connectivity solution for both STAT analyzers ...
... Enterprise is a comprehensive IT solution ... from admission to follow-up. This scalable ... and diagnostic tools from syngo Dynamics ... single, longitudinal clinical repository that becomes ...
Medicine Products: